Publicaciones (77) Publicaciones de ANDRÉS JESÚS MUÑOZ MARTÍN

2024

  1. Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO)

    Thrombosis Update, Vol. 17

  2. Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)

    Clinical and Translational Oncology, Vol. 26, Núm. 9, pp. 2388-2392

  3. Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer

    Thrombosis and Haemostasis, Vol. 124, Núm. 7, pp. 676-683

  4. Immune checkpoint inhibitors-associated thrombosis in patients with head and neck cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group

    Clinical and Translational Oncology

  5. Impact of COVID-19 in the incidence of venous thromboembolism (VTE) and clinical outcomes in cancer patients: a cohort study

    Clinical and Translational Oncology

  6. Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients’ healthcare in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 6, pp. 1319-1328

  7. Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing

    Clinical and Translational Oncology

  8. Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)

    European Journal of Internal Medicine

  9. Up and down in gastrointestinal cancer and bleeding with direct oral anticoagulants

    European Journal of Internal Medicine

  10. Update in venous thromboembolism in cancer: Lessons from multi-centre registries

    Thrombosis Update, Vol. 16

  11. Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 171-177

2023

  1. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2911-2925

  2. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 2007-2019

  3. Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive

    Internal and Emergency Medicine, Vol. 18, Núm. 6, pp. 1619-1634

  4. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10415, pp. 1835-1847

  5. Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents

    Seminars in Oncology, Vol. 50, Núm. 3-5, pp. 67-70

  6. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  7. Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain

    Journal of Medical Economics, Vol. 26, Núm. 1, pp. 1145-1154

  8. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning

    Thrombosis Research, Vol. 228, pp. 181-188

  9. Ictus asociado a cáncer: estudio de prevalencia y factores predictores entre pacientes con ictus isquémico

    Revista de neurologia, Vol. 76, Núm. 6, pp. 189-195